Device Trial Radar · NCT05380960
Blood Hpercoagublity in Copd
Last checked: Nov 19, 2026Latest source record: May 19, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
120
Planned (sponsor's estimate)
Start
Jun 1, 2022
Primary completion
Sep 1, 2023
Study completion Dec 1, 2023
Sponsor
- Lead sponsor
- Assiut UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 19, 2022
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
"The objective of this study is to evaluate the blood coagulability state in patients with COPD admitted at Assiut University Hospital"
Conditions
- Blood Coagulability in Copd
Interventions
cbc coaglation profileDevice
The Demographic, clinical, and laboratory data for the enrolled subjects will be collected. To assess the coagulability state in the participants, we will measure the levels of certain markers in the blood that are thought to be associated with an increased coagulability. A comparison will be made between the different included groups regarding the level of these markers. These markers included complete blood count (CBC) indices (hematocrit, red cell distribution width, platelets count, mean platelet volume and platelet distribution width), C - reactive protein, d dimer, and blood coagulation tests (prothrombin time, international normalized ratio and partial thromboplastin time).
Primary outcomes
What the sponsor says the trial is designed to measure.
- "The objective of this study is to evaluate the blood coagulability state in patients with COPD admitted at Assiut University Hospital"Time frame: baseline
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.